Co-spray dried resveratrol and budesonide inhalation formulation for reducing inflammation and oxidative stress in rat alveolar macrophages

European Journal of Pharmaceutical Sciences

Volumn 86, Issue , 2016, Pages 20-28

  Trotta, Valentina ^a,b,c   Lee, Wing Hin ^a,c   Loo, Ching Yee ^a,c   Young, Paul M ^a,c   Traini, Daniela ^a,c   Scalia, Santo ^b  

^a WOOLCOCK INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b UNIVERSITY OF FERRARA   (Italy)

^c UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Alveolar macrophage; Anti inflammatory; Anti oxidant; Budesonide; Chronic obstructive pulmonary disease; Dry powder inhalation; Resveratrol

Indexed keywords

BUDESONIDE; GELATIN; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; NITRIC OXIDE; RESVERATROL; TUMOR NECROSIS FACTOR ALPHA; AEROSOL; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; STILBENE DERIVATIVE; TUMOR NECROSIS FACTOR;

AEROSOL; ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CELL VIABILITY; CELL VIABILITY ASSAY; CONTROLLED STUDY; CYTOTOXICITY; DPPH RADICAL SCAVENGING ASSAY; DRUG FORMULATION; DRY POWDER INHALER; IN VITRO STUDY; INFLAMMATION; INHALATION; LUNG ALVEOLUS MACROPHAGE; MORPHOLOGY; NONHUMAN; OXIDATIVE STRESS; PARTICLE SIZE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SPRAY DRYING; THERMOSTABILITY; ANIMAL; CELL LINE; CHEMISTRY; DESICCATION; DRUG EFFECTS; INHALATIONAL DRUG ADMINISTRATION; MEDICINAL CHEMISTRY; METABOLISM; PHARMACEUTICS; RAT;

ADMINISTRATION, INHALATION; AEROSOLS; ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTIOXIDANTS; BUDESONIDE; CELL LINE; CHEMISTRY, PHARMACEUTICAL; DESICCATION; INTERLEUKIN-6; LIPOPOLYSACCHARIDES; MACROPHAGES, ALVEOLAR; OXIDATIVE STRESS; RATS; STILBENES; TECHNOLOGY, PHARMACEUTICAL; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84960117440     PISSN: 09280987     EISSN: 18790720     Source Type: Journal    
DOI: 10.1016/j.ejps.2016.02.018     Document Type: Article

References (57)

1. S. Adi, H. Adi, P. Tang, D. Traini, H.-k. Chan, and P.M. Young Micro-particle corrugation, adhesion and inhalation aerosol efficiency Eur. J. Pharm. Sci. 35 2008 12 18
2. C. Alarcón de la Lastra, and I. Villegas Resveratrol as an anti-inflammatory and anti-aging agent: mechanisms and clinical implications Mol. Nutr. Food Res. 49 2005 405 430
3. J. Armstrong, C. Sargent, and D. Singh Glucocorticoid sensitivity of lipopolysaccharide-stimulated chronic obstructive pulmonary disease alveolar macrophages Clin. Exp. Immunol. 158 2009 74 83
4. I.C. Arts, and P.C. Hollman Polyphenols and disease risk in epidemiologic studies Am. J. Clin. Nutr. 81 2005 317S 325S
5. M. Athar, J.H. Back, L. Kopelovich, D.R. Bickers, and A.L. Kim Multiple molecular targets of resveratrol: anti-carcinogenic mechanisms Arch. Biochem. Biophys. 486 2009 95 102
6. P.J. Barnes Chronic obstructive pulmonary disease: a growing but neglected global epidemic PLoS Med. 4 2007 e112
7. P.J. Barnes Role of HDAC2 in the pathophysiology of COPD Annu. Rev. Physiol. 71 2009 451 464
8. P.J. Barnes, K. Ito, and I.M. Adcock Corticosteroid resistance in chronic obstructive pulmonary disease: inactivation of histone deacetylase Lancet 363 2004 731 733
9. P. Basnet, H. Hussain, I. Tho, and N. Skalko-Basnet Liposomal delivery system enhances anti-inflammatory properties of curcumin J. Pharm. Sci. 101 2012 598 609
10. P. Bhavsar, M. Hew, N. Khorasani, A. Torrego, P.J. Barnes, I. Adcock, and K.F. Chung Relative corticosteroid insensitivity of alveolar macrophages in severe asthma compared with non-severe asthma Thorax 63 2008 784 790
11. B. Billack, V. Radkar, and C. Adiabouah In vitro evaluation of the cytotoxic and anti-proliferative properties of resveratrol and several of its analogs Cell. Mol. Biol. Lett. 13 2008 553 569
12. S. Biswas, J.W. Hwang, P.A. Kirkham, and I. Rahman Pharmacological and dietary antioxidant therapies for chronic obstructive pulmonary disease Curr. Med. Chem. 20 2013 1496 1530
13. Z. Budavári, R. Zelko, I. Rácz, and S. Marton Compatibility study between folic acid, vitamin B6 and tablet excipients using differential scanning calorimetry Pharmazie 54 1999 861 862
14. J.J. Cash, M.C. Davis, M.D. Ford, T.J. Groshens, A.J. Guenthner, B.G. Harvey, K.R. Lamison, J.M. Mabry, H.A. Meylemans, and J.T. Reams High T g thermosetting resins from resveratrol Polym. Chem. 4 2013 3859 3865
15. A.M. Cerqueira, N. Khaper, S.J. Lees, and M. Ulanova The antioxidant resveratrol down-regulates inflammation in an in-vitro model of Pseudomonas aeruginosa infection of lung epithelial cells Can. J. Physiol. Pharmacol. 91 2013 248 255
16. H. Cheong, S.Y. Ryu, and K.M. Kim Anti-allergic action of resveratrol and related hydroxystilbenes Planta Med. 65 1999 266 268
17. D.I. Cho, N.Y. Koo, W.J. Chung, T.S. Kim, S.Y. Ryu, S.Y. Im, and K.M. Kim Effects of resveratrol-related hydroxystilbenes on the nitric oxide production in macrophage cells: structural requirements and mechanism of action Life Sci. 71 2002 2071 2082
18. J. Choi, Q. Zhang, V. Reipa, N.S. Wang, M.E. Stratmeyer, V.M. Hitchins, and P.L. Goering Comparison of cytotoxic and inflammatory responses of photoluminescent silicon nanoparticles with silicon micron-sized particles in RAW 264.7 macrophages J. Appl. Toxicol. 29 2009 52 60
19. C.H. Cottart, V. Nivet-Antoine, C. Laguillier-Morizot, and J.L. Beaudeux Resveratrol bioavailability and toxicity in humans Mol. Nutr. Food Res. 54 2010 7 16
20. P. Crosswhite, and Z. Sun Nitric oxide, oxidative stress and inflammation in pulmonary arterial hypertension J. Hypertens. 28 2010 201 212
21. S.V. Culpitt, D.F. Rogers, P.S. Fenwick, P. Shah, C. De Matos, R.E.K. Russell, P.J. Barnes, and L.E. Donnelly Inhibition by red wine extract, resveratrol, of cytokine release by alveolar macrophages in COPD Thorax 58 2003 942 946
22. R. Dahl, K.F. Chung, R. Buhl, H. Magnussen, V. Nonikov, D. Jack, P. Bleasdale, R. Owen, M. Higgins, and B. Kramer Efficacy of a new once-daily long-acting inhaled β2-agonist indacaterol versus twice-daily formoterol in COPD Thorax 65 2010 473 479
23. J.J. Docherty, M.M.H. Fu, B.S. Stiffler, R.J. Limperos, C.M. Pokabla, and A.L. DeLucia Resveratrol inhibition of herpes simplex virus replication Antivir. Res. 43 1999 145 155
24. L.E. Donnelly, R. Newton, G.E. Kennedy, P.S. Fenwick, R.H. Leung, K. Ito, R.E. Russell, and P.J. Barnes Anti-inflammatory effects of resveratrol in lung epithelial cells: molecular mechanisms Am. J. Physiol. Lung Cell. Mol. Physiol. 287 2004 L774 L783
25. A. Ek, K. Larsson, S. Siljerud, and L. Palmberg Fluticasone and budesonide inhibit cytokine release in human lung epithelial cells and alveolar macrophages Allergy 54 1999 691 699
26. S.A. Faith, T.J. Sweet, E. Bailey, T. Booth, and J.J. Docherty Resveratrol suppresses nuclear factor-kappa B in herpes simplex virus infected cells Antivir. Res. 72 2006 242 251
27. T. Harju, R. Kaarteenaho-Wiik, Y. Soini, R. Sormunen, and V.L. Kinnula Diminished immunoreactivity of γ-glutamylcysteine synthetase in the airways of smokers' lung Am. J. Respir. Crit. Care Med. 166 2002 754 759
28. S. Hodge, G. Hodge, J. Ahern, H. Jersmann, M. Holmes, and P.N. Reynolds Smoking alters alveolar macrophage recognition and phagocytic ability: implications in chronic obstructive pulmonary disease Am. J. Respir. Cell Mol. 37 2007 748 755
29. M.W. Joraholmen, N. Škalko-Basnet, G. Acharya, and P. Basnet Resveratrol-loaded liposomes for topical treatment of the vaginal inflammation and infections Eur. J. Pharm. Sci. 79 2015 112 121
30. L. Kent, L. Smyth, C. Clayton, L. Scott, T. Cook, R. Stephens, S. Fox, P. Hext, S. Farrow, and D. Singh Cigarette smoke extract induced cytokine and chemokine gene expression changes in COPD macrophages Cytokine 42 2008 205 216
31. O. Khair, R. Davies, and J. Devalia Bacterial-induced release of inflammatory mediators by bronchial epithelial cells Eur. Respir. J. 9 1996 1913 1922
32. J. Knobloch, B. Sibbing, D. Jungck, Y. Lin, K. Urban, E. Stoelben, J. Strauch, and A. Koch Resveratrol impairs the release of steroid-resistant inflammatory cytokines from human airway smooth muscle cells in chronic obstructive pulmonary disease J. Pharmacol. Exp. Ther. 335 2010 788 798
33. J. Knobloch, H. Hag, D. Jungck, K. Urban, and A. Koch Resveratrol impairs the release of steroid-resistant cytokines from bacterial endotoxin-exposed alveolar macrophages in chronic obstructive pulmonary disease Basic Clin. Pharmacol. Toxicol. 109 2011 138 143
34. A. Kode, S. Rajendrasozhan, S. Caito, S.R. Yang, I.L. Megson, and I. Rahman Resveratrol induces glutathione synthesis by activation of Nrf2 and protects against cigarette smoke-mediated oxidative stress in human lung epithelial cells Am. J. Physiol. Lung Cell. Mol. Physiol. 294 2008 L478 L488
35. M. Lee, S. Kim, O.K. Kwon, S.R. Oh, H.K. Lee, and K. Ahn Anti-inflammatory and anti-asthmatic effects of resveratrol, a polyphenolic stilbene, in a mouse model of allergic asthma Int. Immunopharmacol. 9 2009 418 424
36. Y.-H. Li, Z.-Q. Yan, A. Brauner, and K. Tullus Activation of macrophage nuclear factor-κB and induction of inducible nitric oxide synthase by LPS Respir. Res. 3 2002 23
37. C.M. Lilly, H. Nakamura, H. Kesselman, C. Nagler-Anderson, K. Asano, E.A. Garcia-Zepeda, M.E. Rothenberg, J.M. Drazen, and A.D. Luster Expression of eotaxin by human lung epithelial cells: induction by cytokines and inhibition by glucocorticoids J. Clin. Invest. 99 1997 1767
38. M. Linden, and R. Brattsand Effects of a corticosteroid, budesonide, on alveolar macrophage and blood monocyte secretion of cytokines - differential sensitivity of Gm-Csf, Il-1-beta, and Il-6 Pulm. Pharmacol. 7 1994 43 47
39. P.L. Liu, J.R. Tsai, A.L. Charles, J.J. Hwang, S.H. Chou, Y.H. Ping, F.Y. Lin, Y.L. Chen, C.Y. Hung, W.C. Chen, Y.H. Chen, and I.W. Chong Resveratrol inhibits human lung adenocarcinoma cell metastasis by suppressing heme oxygenase 1-mediated nuclear factor-kappa B pathway and subsequently downregulating expression of matrix metalloproteinases Mol. Nutr. Food Res. 54 2010 S196 S204
40. W. MacNee Oxidative stress and lung inflammation in airways disease Eur. J. Pharmacol. 429 2001 195 207
41. S.K. Manna, A. Mukhopadhyay, and B.B. Aggarwal Resveratrol suppresses TNF-induced activation of nuclear transcription factors NF-kappa B, activator protein-1, and apoptosis: potential role of reactive oxygen intermediates and lipid peroxidation J. Immunol. 164 2000 6509 6519
42. A.R. Neves, M. Lucio, J.L.C. Lima, and S. Reis Resveratrol in medicinal chemistry: a critical review of its pharmacokinetics, drug-delivery, and membrane interactions Curr. Med. Chem. 19 2012 1663 1681
43. L.M. Nolan, L. Tajber, B.F. McDonald, A.S. Barham, O.I. Corrigan, and A.M. Healy Excipient-free nanoporous microparticles of budesonide for pulmonary delivery Eur. J. Pharm. Sci. 37 2009 593 602
44. C. Parlati, P. Colombo, F. Buttini, P.M. Young, H. Adi, A.J. Ammit, and D. Traini Pulmonary spray dried powders of tobramycin containing sodium stearate to improve aerosolization efficiency Pharm. Res. 26 2009 1084 1092
45. R.A. Pauwels, C.-G. Löfdahl, L.A. Laitinen, J.P. Schouten, D.S. Postma, N.B. Pride, and S.V. Ohlsson Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking N. Engl. J. Med. 340 1999 1948 1953
46. R.A. Pauwels, A.S. Buist, P.M.A. Calverley, C.R. Jenkins, and S.S. Hurd Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease Am. J. Respir. Crit. Care Med. 163 2001 1256 1276
47. X. Peng, R.-E.E. Abdulnour, S. Sammani, S.-F. Ma, E.J. Han, E.J. Hasan, R. Tuder, J.G.N. Garcia, and P.M. Hassoun Inducible nitric oxide synthase contributes to ventilator-induced lung injury Am. J. Respir. Crit. Care Med. 172 2005 470 479
48. B. Pharmacopoeia Section 2.9. 18-Appendix XII C. Consistency of formulated preparations for inhalation 2009
49. K.F. Rabe, S. Hurd, A. Anzueto, P.J. Barnes, S.A. Buist, P. Calverley, Y. Fukuchi, C. Jenkins, R. Rodriguez-Roisin, C. Van Weel, and J. Zielinski Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease Am. J. Respir. Crit. Care Med. 176 2007 532 555
50. I. Rahman, and I.M. Adcock Oxidative stress and redox regulation of lung inflammation in COPD Eur Respir J 28 2006 219 242
51. I. Rahman, and W. MacNee Role of transcription factors in inflammatory lung diseases Thorax 53 1998 601 612
52. R.O. Salama, P.M. Young, and D. Traini Concurrent oral and inhalation drug delivery using a dual formulation system: the use of oral theophylline carrier with combined inhalable budesonide and terbutaline Drug Deliv. Transl. Res. 4 2014 256 267
53. T.D. Tetley Macrophages and the pathogenesis of COPD Chest 121 2002 156S 159S
54. V. Trotta, W.-H. Lee, C.-Y. Loo, M. Haghi, P.M. Young, S. Scalia, and D. Traini In vitro biological activity of resveratrol using a novel inhalable resveratrol spray-dried formulation Int. J. Pharm. 491 2015 190 197
55. G. Viegi, A. Scognamiglio, S. Baldacci, F. Pistelli, and L. Carrozzi Epidemiology of chronic obstructive pulmonary disease (COPD) Respir. Int. Rev. Thorac. Dis. 68 2001 4 19
56. C. Vogelmeier, B. Hederer, T. Glaab, H. Schmidt, M.P. Rutten-van Mölken, K.M. Beeh, K.F. Rabe, and L.M. Fabbri Tiotropium versus salmeterol for the prevention of exacerbations of COPD N. Engl. J. Med. 364 2011 1093 1103
57. A. Zetterlund, P.H. Larsson, C. Müller-Suur, L. Palmberg, and K. Larsson Budesonide but not terbutaline decreases phagocytosis in alveolar macrophages Respir. Med. 92 1998 162 166